Protara Therapeutics, Inc. — Director's Dealing 2021

Jan 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2021-01-19

Reporting Person: Davis Blaine (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-19	Stock Option (Right to Buy)	$19.82	A	75000	Acquired	2031-01-18	Common Stock (75000)	Direct

Footnotes

F1: 25% of the shares vest on the one year anniversary of January 19, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.